Mobile website
Clinical Research
Expression of ATPase F1α in human colorectal cancer tissues and cell line and its clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To observe the expression of ATPase F1α in colorectal cancer (CRC) tissues and in LoVo cells, and to discuss its clinical significance. Methods: Expression of ATPase F1α protein in 44 CRC specimens and their adjacent normal tissues (August 2007 to December 2007, Changhai Hospital) and ATPase F1α mRNA in 8 colorectal cancer tissues and their adjacent normal tissues were examined by immunohistochemistry EnVision assay and RTPCR, respectively. Expression of ATPase F1α on the cell surface of LoVo cells was observed by immunofluorescence. The inhibitory effect of antiATPase F1α antibody on the proliferation of LoVo cells was evaluated by CCK8 assay. Results: Expression of ATPase F1α in the 44 CRCs were significantly higher than those in the adjacent normal tissues as detected by immunohistochemistry (P<0.01). Thirtyfive samples (79.5%) in 44 CRCs and 15 samples (34.1%) in their adjacent normal tissues showed moderate to high expression of ATPase F1α. Expression of ATPase F1α mRNA in 8 CRCs was significantly higher than those in their adjacent normal tissues (P<0.01). Positive rate of ATPase F1α mRNA in CRCs was significantly higher than that of CEA in the same patients before surgery (P<0.01). There was no correlation of ATPase F1α expression with the age, gender, tumor stage, lymphoid metastasis, remote metastasis, tumor location and tumor differentiation of colorectal cancer (P>0.05). Expression of ATPase F1α was observed on the cell surface of LoVo cells, and antiATPase F1α antibody significantly inhibited the proliferation of LoVo cells (P<0.01). Conclusion: ATPase F1α is highly expressed in colorectal cancer tissues and cell line. As a tumor association antigen, ATPase F1α may serve as a new target in colorectal cancer immunotherapy.
Keywords:
Project Supported:
Supported by the Medical Science Research the “11th FiveYear Plan” of PLA (No.01MA159)
Clc Number:
